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Abstract 
Objective: To determine the role of regulatory B cell derived interleukin (Il)-10 in 
atherosclerosis. 
Approach and Results: We created chimeric Ldlr-/- mice with a B cell-specific deficiency in 
Il-10, and confirmed that purified B cells stimulated with LPS failed to produce IL-10 
compared to control Ldlr-/- chimeras. Mice lacking B cell Il-10 demonstrated enhanced 
splenic B cell numbers but no major differences in B cell subsets, T cell or monocyte 
distribution, and unchanged body weights or serum cholesterol levels compared to control 
mice. After 8 weeks on high fat diet, there were no differences in aortic root or aortic arch 
atherosclerosis. In addition to plaque size, plaque composition (macrophages, T cells, 
smooth muscle cells and collagen) was similar between groups. 
Conclusions: In contrast to its prominent regulatory role in many immune-mediated 
diseases and its proposed modulatory role in atherosclerosis, B cell derived Il-10 does not 
alter atherosclerosis in mice. 
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Atherosclerotic inflammation induces the recruitment and activation of adaptive (T and B 
cell) immunity. In humans, this is linked to clinically deleterious states of cardiovascular 
disease, for example unstable plaque1,2. A key process may be the loss of tolerance to self 
antigens and progressive development of pro-inflammatory adaptive responses, whereby 
innate antigen presenting cells and the cytokine and danger-associated molecular patterns 
milieu favours Th1-type CD4+ helper cells3,4. Like the more extensively characterized 
regulatory T cells, regulatory B (Breg) cells dampen dendritic cell and T cell activation. A 
major anti-inflammatory effector mechanism utilized by regulatory B cells is the secretion of 
interleukin (Il)-10. B10 cells are a functionally defined population and include all B cells with 
the capacity to produce Il-10. They are enriched within the CD1dhi CD5+ population but they 
are not restricted to it5. B cell Il-10 production has been shown to protect against 
autoimmune disease development6–8 including models of diabetes and adipose 
inflammation9.  
B2 cell depletion is atheroprotective whereas complete B cell deficiency, i.e. both B1 and B2 
cells, promotes atherosclerosis10–14. B cells therefore have multiple and opposing influences 
on atherosclerotic plaque development15. Immunoglobulin (Ig)M production by B1 cells is a 
major protective mechanism, whereas promotion of effector T cell responses may mediate 
the pro-atherogenic potential of B2 cells. B1 cells can also produce substantial levels of Il-
106,8 and the presence of a Breg cell subset among the B2 cell population suggests a 
potential counter-regulatory role in atherosclerosis. A recent study showed that reduction of 
aortic B1a and Breg cells was associated with reduced T15 IgM antibody and Il-10 levels, 
and increased atherosclerosis16. We and others have previously shown an anti-atherogenic 
role for Il-1017,18, primarily when expressed by regulatory T cells19 or macrophages20. To date 
there have been no reports on the role of Il-10 from B cells or the role of Breg cells in 
atherosclerosis. Here, we show that contrary to current belief, B cell-restricted deficiency in 
Il-10 does not modulate atherosclerotic plaque development or modulate plaque phenotype.  
Materials and Methods 
Materials and Methods are available in the online-only Data Supplement. 
Results 
We first investigated whether regulatory B cells with Il-10 producing capability were present 
in atherosclerotic mice. In Ldlr-/- mice after 6 weeks of chow or high fat diet, we found a 
significant population of Il-10+ B cells in the spleen by intracellular flow cytometry, with no 
differences between chow and high fat diet-fed animals (Figure 1A). This indicates that 
innate B cells maintain high production of Il-10 in the presence of an inflammatory 
atherosclerotic setting.  
To determine the specific role of B cell-derived Il-10 in atherosclerosis, we employed a 
previously characterized mixed bone marrow chimera approach6,13. Ldlr-/- male mice were 
irradiated and reconstituted with 80% B cell deficient (μMT) bone marrow cells and either 
20% WT mice (‘Ldlr/BWT’) or 20% Il-10-/- bone marrow (‘Ldlr/BIl10-/-’) (see methods). After 4 
weeks recovery, mice were fed a high fat diet for 8 weeks. Circulating metabolic parameters 
(total cholesterol, high density lipoprotein-cholesterol, insulin, glucose) and animal weights 
were similar between the two groups of mice (Figure I in the online-only Data Supplement 
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and data not shown). As expected, there were no differences in the number of Breg (CD19+ 
CD1dhi CD5+; see Figure IIA in the online-only Data Supplement for an example) in spleen or 
lymph nodes (Figure 1B and IIB in the online-only Data Supplement). Similar results were 
found with alternative gating (CD23hi CD21hi CD24hi; data not shown). However, Il-10 
production in response to LPS was reduced 20-fold (mRNA levels) and 70-fold (protein 
levels) in B cells purified from the spleens of Ldlr/BIl10-/- compared to Ldlr/BWT mice (Figure 
1C and data not shown) without any difference in IgM production (Figure 1C). There were no 
differences in Il-10 production by T cells (Figure IIC in the online-only Data Supplement) but 
circulating levels of IL-10 in serum were significantly reduced in Ldlr/BIl10-/- compared to 
Ldlr/BWT mice (Figure IID in the online-only Data Supplement). There was a small increase in 
total splenic B cells (Figure 1D), most likely due to an expansion of the follicular subset 
(Figure 1E). There were no differences in circulating monocytes but we observed a 
significant decrease in blood neutrophil numbers (Figure IIE in the online-only Data 
Supplement). 
In other disease contexts, Breg cells have been reported to be important regulators of 
autoimmune T cell responses. However, in the context of atherosclerosis, we did not find 
any significant impact on dendritic cell or T cell activation levels (Figure III in the online-only 
Data Supplement) or T helper polarization (data not shown). Accordingly, we did not see any 
significant changes in atherosclerosis development in the aortic root (Figure 2A), or in the 
aortic arch (Figure 2B). In the descending aorta, we observed a 1.4 fold increase in relative 
mRNA levels of inflammatory markers Ccl2 and Tnf but not Vcam-1 or Il6 (Figure 2C), 
indicating some impact of B cell Il-10 deficiency in this location. However, this change was 
balanced by a 1.6-fold increase in Il10, presumably from other cell sources, suggesting that 
the overall influence of local cytokines is not changed in the BIL10-/- group. Indeed, although 
Il-10 mRNA expression was increased in the spleens of high fat diet compared to chow-fed 
mice, analysis of B cells purified by negative magnetic bead-mediated separation and the 
corresponding positive fraction of non-B cells (see methods in the online-only Data 
Supplement) indicated that the increased IL-10 expression derives primarily from non-B cells 
(Figure IV in the online-only Data Supplement). In order to determine if plaque morphology 
was different, we analysed proportions of plaque macrophages, T cells, smooth muscle cells 
and collagen content, but found no significant differences between groups (Figure 2D). We 
conclude that in contrast to other cellular sources of Il-10, regulatory B cell-derived Il-10 
does not affect atherosclerosis development in Ldlr-/- mice.   
Discussion 
The oxidative modification of low density lipoprotein and the accumulation of necrotic cell 
debris exposes common immunogenic epitopes recognised by both natural and adaptive 
(induced) antibodies. These antibodies are produced by active B cell responses that also 
produce Il-10 secreting Breg cells. This study is the first to show that this regulatory B cell Il-
10 response does not modulate early atherosclerosis development, a period during which 
significant pathogenic and protective B cell responses are induced and regulate plaque 
progression. 
B cells modulate atherosclerosis through several modalities. This is reflected in the 
apparently paradoxical results of different B cell-modulating strategies leading to either 
enhanced or decreased atherosclerosis10–15,21. A clear role for IgM primarily from B1a 
plasma cells found in the spleen and bone marrow is now recognised, a role for spleen 
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resident granulocyte-macrophage colony stimulating factor-producing innate activator B cells 
in enhancing dendritic cell activation has recently been described22, and while not proven 
directly a role for adaptive IgG responses and direct regulation of T cells also likely 
contribute to B cell regulation of atherosclerosis23. In the case of suppressive B cells, some 
reports suggest that IgM production is essential24,25, whereas others show reduced 
atherosclerosis through IgM-independent pathways21. Most recently, Gjurich et al16 show 
that, among other defects, L-selectin-/- mice with enhanced atherosclerosis lack aortic 
migration of IgM producing B1a cells and Il-10 producing Breg cells. Our results suggest that 
these pro-atherogenic effects are not mediated through Il-10 producing Bregs. However, we 
cannot rule out Il-10 independent effects of Breg cells, e.g. Il-3526. More work is needed to 
define the activation status and migratory potential of B10 cells in the context of 
atherosclerosis, in order to better understand their differential impact on disease 
development compared to other inflammatory conditions. The role of gut-derived B cell 
responses in atherosclerosis has yet to be investigated. Interestingly, regulatory B cells are 
much less suppressive against arthritis when derived from ‘specific pathogen free’ housed 
mice compared to conventionally housed mice8. This may be due in part to differences in gut 
microbiota. It will be interesting to see if B cell Il-10 has any role in conventionally housed 
atherosclerotic mice. 
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Significance 
B cell responses are now recognised to have both protective and pathogenic influences on 
atherosclerosis development. Given the importance of the regulatory arm of T cell immunity, 
it is significant to find that in fact Il-10-dependent regulatory responses of B cells are not 
important in atherosclerosis. This gives further insight into the potential consequences of 
targeting B cells in human cardiovascular disease patients. 
 
Figure Legends 
Figure 1. A. Levels of Il-10 producing B cells (CD19+) in the spleens of Ldlr-/- mice fed chow 
or high fat diet for 6 weeks, quantified by intracellular flow cytometry after 4h ex vivo LPS 
stimulation (see methods). B-E. Analysis of B cells from Ldlr-/- chimeric mice with µMT/WT 
(BWT) or µMT/IL-10-/- (BIL-10-/-) bone marrow after 8 weeks high fat diet. B. Regulatory B cell 
levels (CD19+ CD1dhi CD5+) in spleens. C. Il-10 and IgM production by B cells purified from 
spleens treated with or without LPS (1 µg/ml). D. Spleen B cell (B220+ IgM+) levels. E. 
Spleen B cell subsets defined by gating on CD23 and CD21 expression: T1 (CD23- CD21-), 
T2 (CD23+ CD21hi), marginal zone (CD23lo CD21hi) and follicular (CD23+ CD21lo). *p<0.05. 
Figure 2. Analysis of atherosclerotic plaques of Ldlr-/- chimeric mice with µMT/WT (BWT) or 
µMT/IL-10-/- (BIL-10-/-) bone marrow after 8 weeks high fat diet. A. Aortic plaque area 
quantified on 10 cryosections (n=10/group). B. En-face lesion area in the aortic arches. C. 
Quantitative PCR analysis of descending aorta RNA levels. D. Macrophage (MOMA2+), T 
cell (CD3+), smooth muscle cell (α-sma+) and collagen (picrosirius red) content of aortic root 
plaques. *p<0.05. 
